RHYTHM PHARMACEUTICALS, INC.
Develops precision medicines for rare genetic diseases causing severe obesity and hyperphagia.
RYTM | NDAQ
Overview
Corporate Details
- ISIN(s):
- US76243J1051
- LEI:
- Country:
- United States of America
- Address:
- 222 BERKELEY STREET, 2116 BOSTON
- Website:
- https://rhythmtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing precision medicines for rare neuroendocrine diseases. The company focuses on treating conditions characterized by hyperphagia (insatiable hunger) and severe obesity that stem from rare genetic deficiencies. Its lead therapeutic, setmelanotide (marketed as IMCIVREE), is a precision medicine designed to address the root cause of these disorders by targeting the melanocortin-4 receptor (MC4R) pathway. Rhythm is advancing a portfolio of treatment options to transform the lives of patients and families affected by these debilitating conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Automate Your Workflow. Get a real-time feed of all RHYTHM PHARMACEUTICALS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for RHYTHM PHARMACEUTICALS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for RHYTHM PHARMACEUTICALS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
